CD34 and acute lymphoblastic leukemia: To further confirm clinical translatability, a humanized TIE2.IFN‐γ construct was designed, validated for functionality and absence of toxicity on human culture‐derived M2 macrophages and CD34+ HSPC, and tested in a therapeutically relevant model of human B‐ALL, in combination with CD19 CAR‐T cells (Fig EV3F–L).